Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.43 |
| ▸ | MMP2 | P08253 | 7/20 | 0.39 |
| ▸ | MMP9 | P14780 | 7/20 | 0.39 |
| ▸ | MMP8 | P22894 | 7/20 | 0.39 |
| ▸ | MMP13 | P45452 | 7/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26382133 | 0.94 | DGAT1 (0.46) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL12392769 | 0.91 | DGAT1 (0.41) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL24372151 | 0.88 | NCF1 (0.43) | DGAT1ABCB1ABCC1ABCG2NCF1 | |
| SCHEMBL25911678 | 0.87 | DGAT1 (0.40) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL25890693 | 0.87 | DGAT1 (0.41) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL25974534 | 0.87 | DGAT1 (0.46) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL21099971 | 0.87 | DGAT1 (0.43) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL12392763 | 0.86 | NPC1 (0.42) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL23157304 | 0.86 | DGAT1 (0.37) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL25446426 | 0.85 | DGAT1 (0.46) | DGAT1MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | FUT5, FUT6, SIGLEC7 | DGAT1 1513/4885MMP2 3684/4885MMP9 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.